

Summit Corporation plc
(‘Summit’ or ‘the Company’)

APPLICATION TO TRADING

Oxford, UK, 23 April 2012, Summit (AIM: SUMM), a UK drug discovery company, announces that, further to the passing of the resolutions at the General Meeting of the Company on 20 April 2012, application has been made for 166,666,670 new Ordinary Shares to be admitted to trading on the AIM market of the London Stock Exchange. Admission to trading is expected to take place at 8.00 a.m. on 24 April 2012.

Following admission, the Company will have 354,088,450 Ordinary Shares in issue.

- END -

For more information, please contact:

Summit

Glyn Edwards / Richard Pye

Tel: +44 (0)1235 443 939

Singer Capital Markets

(Nominated Adviser and Joint broker)

Shaun Dobson / Claes Spång

Tel: +44 (0)203 205 7500

Hybridan LLP

(Joint broker)

Claire Louise Noyce / Deepak Reddy

Tel: +44 (0)207 947 4350

Peckwater PR

(Financial public relations)

Tarquin Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

Notes to Editors

About Summit

Summit is an Oxford, UK based drug discovery Company with an innovative Seglin™ technology platform for the discovery of new medicines and a portfolio of drug programme assets. Summit’s programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and *C. difficile* infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.